Professional Documents
Culture Documents
UBS Global Generic and Specialty Pharmaceuticals Conference New York May 8, 2007
Safe Harbor
Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as will, aim, will likely result, would, believe, may, expect, will continue, anticipate, estimate, intend, plan,
contemplate, seek to, future, objective, goal, likely, project, should, potential, will pursue and similar expressions or variations of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could
cause actual results to differ materially from those suggested by the forward-looking statements. These
risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. Ranbaxy does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.
30 25 20 15 10 5 0
2006 2007 2008 2009 2010 2011
$ Bn
Source : IMS
Increasing genericisation
France Spain Italy
Key Issues
Increasing competition
00/01
90/01 80/01
11,412
5,932 4,861
05/06
00/01 90/01 80/01
10,500
7,500 4,000 3,000
+40%
Number of Institutions courses 05/06 Pharmacy Medicine 1478 229 99/00 669 174 +120% +32%
Physiotherapy
205
52
+294%
90/01
(USA 03/04
2950
25,000)
Engineers/Science graduates p.a. India 0.7 mn, China 0.5 mn, EU 0.5 mn, USA 0.4 mn, Japan 0.3 mn
Highest No
of DMF filings
144
120
80
64 46
40
24
One in every four ANDAs filed by Indian Companies in top US FDA filers
(Source: KPMG)
No Chinese generic company has yet filed a US FDA ANDA but expected in 2008
Ranbaxy Today
Worldwide Presence
Amongst Top 10 Global Gx companies Ground presence in 49 countries, products sold in > 125 International business ~ 80% of sales Manufacturing locations in 11 countries
Global Sales
$ 1339
> 11,000 employees, 51 nationalities Strong Generics & Innovative research capabilities
$ 972
$ 553
2001
2003
2006
Highlights - 2006
$ Mn
2005^ 1145 7% 60
% +17% +90%
Financials
Markets
markets
Exclusivity in Simvastatin 80 mg tablets Inorganic impetus
* % sales, ^ excludes sales from discontinued operations .i.e . Allied Businesses divested in 2005
2006
2005
% Bio-Studies (BA/BE^) conducted 2006 In-House Overseas CRO Indian CRO 71% 8% 21% 2005 28% 61% 11%
Advanced Markets
Increasing sourcing from low cost countries .i.e. India & China
35%
65%
2005
2008*
6% 27%
Asia $367, +19%
+20% - 9% + 17%
7% 27%
Asia $367, +19%
332 23 355
USA
Sales
Strong growth in USA, +15% Simvastatin 80 mg 180 day exclusivity - Market Share (MS) of 56% Increasing No of Prescriptions
- Q1 2005 - 10.8 Mn - Q1 2006 - 12.5 Mn - Q1 2007 - 14.1 Mn
$ 380 $ 332
+15%
OTC
- 20 FTF US$ 26 Bn
~ 20 FTF ANDAs 2006 - 27 filings - 10 approvals
USA
Products pending approval
200 160
# of ANDAs
120
80
40
0
Teva Ranbaxy Sun Mylan Watson DRL Barr Par
USA
Potential FTF Challenges
45
36
# of FTFs
27
18
yl an
so n
va
xy
Pa r
R L
ar r
an ba
Te
at
Su
European Union
Presence in 23 of the 27 EU countries
300
Sales
$ 267
Romania
$ 214
150
Major countries
- Germany : AOK business - France - UK : Supplies from India : Gabapentin launch
100
50
$ Mn
2006
2005
India
Fastest growing Company in India on MAT basis
(Source :ORG-IMS Mat Mar 2007) Ranbaxy GSK 5.0% Cipla 4.9% 5.1%
No 1 NDDS Company with 8% MS. Contribution to total sales ~ 9% Dedicated task forces for Specialized & Chronic therapies
R&D III
R&D I
R&D II
R&D IV
Out-licensing
in DDR
Status
Under Phase II B trials (with Piperaquine) IND approval received from DCGI* (India) in May 06 Phase I trials
Remarks
Agreement for part funding by DST*
Out-licensing opportunity
(Urinary Incontinence)
Candidate Selection
GSK Program - COPD / Asthma RBx 10017876 - Inhalation PDE IV B, COPD/ Asthma RBx 10020025 - Tiotropium like , MRA inh., COPD / Asthma RBx 10014255 - Anti infective, Macrolide / Ketolide RBx 10019821 - Diabetes, DPP IV
being explored
API
Approvals 5 117 12 22
Total
617
587
171
156
Excludes India for API approvals, EU filings and approvals include Mutual Recognition Procedure (MRP) and De-centralized Procedure (DCP) filings and approvals.
Terapia (Romania)
Zenotech (India)
Krebs (India) Jupiter Biosciences*(Ind.) Cardinal Drugs (India) Auto-injector Tech.(USA)
Niche Alliances
Increasing focus on chronic / lifestyle diseases segment High entry barriers - technology & resource intensive
Jupiter* Peptides
Limuses
Financials
Figures in US$ Mn
2006
1339 207
16%
%
17% 144% 481%
Q1 2007
355 43
12%
%
24% 35% 102%
OPBT*
131
36
PBT
144
226%
37
94%
PAT
114
90%
29
81%
* 2005 sales excludes sales from discontinued operations .i.e Allied Businesses. OPBT Operating profit before tax
In Summary
A strong 2006 performance on all parameters Buoyant performance across key geographies Continuing focus on cost optimization Robust product flow Growth through organic & inorganic Discovery pipeline progressing well Global Generic rank 9th / 10th
Thank You
Ranbaxy at the UBS Global Generic and Specialty Pharmaceuticals Conference New York May 8, 2007